What's New in Therapeutic Options for Moderate to Severe RA?

Introduction/Overview

Taxonomy of Inadequate Responders to RA Therapeutics

Different RA Combination Treatments Centered on MTX

EULAR Recommendations: 2016

Earlier Identification of the Individual at Risk for RA

Identification of Patients at Risk for Rapid RA Progression

Approaches for the Non-Responding Patient With RA

Many Cytokines and Growth Factors Converge on JAK Signaling Pathways

The Biological Significance of Signaling Through Different JAK Combinations

Baricitinib (JAK 1/2 Inhibitor): Key Studies in RA Phase 3 Program and Their Characteristics

RA-BEACON: Study Design

RA-BEACON: Baricitinib in Patients With RA and an Inadequate Response to TNF-a Inhibitors

Potential Benefits of the JAK 1/2 Inhibitor Baricitinib

Tofacitinib (JAK1/3 Inhibitor): Key Studies in RA Phase 3 Program and Their Characteristics

ORAL Scan: Change in Radiographic Progression, Tofacitinib (5 mg, 10 mg) vs Placebo

Tofacitinib or ADA vs PBO in RA: Results From ORAL Standard

Comparing Clinical Results of JAK1/3 and JAK1/2 Inhibitors

DARWIN 1 Phase 2: ACR Outcomes at Week 12 in MTX-IR: Filgotinib + MTX in Patients With Active RA

Other JAK Inhibitors in Development: Upadacitinib

JAK Inhibitors: Safety Considerations

Types of Therapies for RA

EULAR Recommendations 2016: What to Do After MTX Failure

Appropriate Management of RA

Summary and Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)